CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3–2.5, P=0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Maisey, N R, Norman, A R, Hill, A, Massey, A, Oates, J, Cunningham, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361637/
https://www.ncbi.nlm.nih.gov/pubmed/16175188
http://dx.doi.org/10.1038/sj.bjc.6602760
_version_ 1782153262713012224
author Maisey, N R
Norman, A R
Hill, A
Massey, A
Oates, J
Cunningham, D
author_facet Maisey, N R
Norman, A R
Hill, A
Massey, A
Oates, J
Cunningham, D
author_sort Maisey, N R
collection PubMed
description In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3–2.5, P=0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS (HR 1.9; 95% CI: 1.1–3.4, P=0.019).
format Text
id pubmed-2361637
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23616372009-09-10 CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials Maisey, N R Norman, A R Hill, A Massey, A Oates, J Cunningham, D Br J Cancer Clinical Study In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3–2.5, P=0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS (HR 1.9; 95% CI: 1.1–3.4, P=0.019). Nature Publishing Group 2005-10-03 2005-09-20 /pmc/articles/PMC2361637/ /pubmed/16175188 http://dx.doi.org/10.1038/sj.bjc.6602760 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Maisey, N R
Norman, A R
Hill, A
Massey, A
Oates, J
Cunningham, D
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
title CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
title_full CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
title_fullStr CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
title_full_unstemmed CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
title_short CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
title_sort ca19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361637/
https://www.ncbi.nlm.nih.gov/pubmed/16175188
http://dx.doi.org/10.1038/sj.bjc.6602760
work_keys_str_mv AT maiseynr ca199asaprognosticfactorininoperablepancreaticcancertheimplicationforclinicaltrials
AT normanar ca199asaprognosticfactorininoperablepancreaticcancertheimplicationforclinicaltrials
AT hilla ca199asaprognosticfactorininoperablepancreaticcancertheimplicationforclinicaltrials
AT masseya ca199asaprognosticfactorininoperablepancreaticcancertheimplicationforclinicaltrials
AT oatesj ca199asaprognosticfactorininoperablepancreaticcancertheimplicationforclinicaltrials
AT cunninghamd ca199asaprognosticfactorininoperablepancreaticcancertheimplicationforclinicaltrials

Ejemplares similares